MK-7075 (miransertib)

DRUG2 trials

Sponsors

National Human Genome Research Institute (NHGRI)

Conditions

Proteus Syndrome

Phase 1

Dose Finding Trial of MK-7075 in Children and Adults With Proteus Syndrome

CompletedNCT02594215

National Human Genome Research Institute (NHGRI)Proteus Syndrome

Start: 2015-11-16End: 2022-06-24Updated: 2022-06-30

Phase 2

MK-7075 (Miransertib) in Proteus Syndrome

Active, not recruitingNCT04316546

National Human Genome Research Institute (NHGRI)Proteus Syndrome

Start: 2022-05-20End: 2028-07-01Updated: 2026-07-17